IL86211A - Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation - Google Patents

Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation

Info

Publication number
IL86211A
IL86211A IL86211A IL8621188A IL86211A IL 86211 A IL86211 A IL 86211A IL 86211 A IL86211 A IL 86211A IL 8621188 A IL8621188 A IL 8621188A IL 86211 A IL86211 A IL 86211A
Authority
IL
Israel
Prior art keywords
forms
administration
carbamazepine
preparation
aqueous suspension
Prior art date
Application number
IL86211A
Other languages
English (en)
Other versions
IL86211A0 (en
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of IL86211A0 publication Critical patent/IL86211A0/xx
Publication of IL86211A publication Critical patent/IL86211A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL86211A 1987-05-04 1988-04-28 Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation IL86211A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH168287 1987-05-04

Publications (2)

Publication Number Publication Date
IL86211A0 IL86211A0 (en) 1988-11-15
IL86211A true IL86211A (en) 1992-03-29

Family

ID=4216129

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86211A IL86211A (en) 1987-05-04 1988-04-28 Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation

Country Status (21)

Country Link
US (1) US5122543A (no)
EP (1) EP0289977B1 (no)
JP (1) JPH01131117A (no)
KR (1) KR960006059B1 (no)
AT (1) ATE94390T1 (no)
AU (1) AU619178B2 (no)
CA (1) CA1328219C (no)
DD (1) DD269784A5 (no)
DE (1) DE3884044D1 (no)
DK (1) DK169608B1 (no)
ES (1) ES2043716T3 (no)
FI (1) FI882044A (no)
HU (1) HU199074B (no)
IE (1) IE63081B1 (no)
IL (1) IL86211A (no)
MX (1) MX11339A (no)
NO (1) NO881933L (no)
NZ (1) NZ224476A (no)
PH (1) PH24895A (no)
PT (1) PT87381B (no)
ZA (1) ZA883135B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4422881A1 (de) * 1993-10-25 1995-04-27 Bayer Ag Kolloidal dispergierbare Wirkstoff-Formulierungen
US5952004A (en) * 1994-03-18 1999-09-14 Shire Laboratories Inc. Emulsified drug delivery systems
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
IL136807A0 (en) * 1997-12-19 2001-06-14 Taro Pharmaceuticals Usa Inc Topical carbamazepine formulation and methods of use
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
WO2002055059A2 (en) * 2000-12-22 2002-07-18 Baxter Int Method for preparing submicron particle suspensions
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
IN190699B (no) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en) * 2001-09-26 2004-06-23 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
WO2003075830A2 (en) * 2002-03-14 2003-09-18 Sun Pharmaceutical Industries Limited Oral controlled drug delivery system containing carbamazepine
CA2608930A1 (en) * 2005-06-14 2006-12-28 Baxter International Inc. Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
JP2009516003A (ja) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド リポキシゲナーゼ阻害剤の組成物
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US8426467B2 (en) * 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) * 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US9394327B1 (en) * 2013-03-15 2016-07-19 The Trustees Of California State University Nucleoside crystals, crystal nucleation and growth control with antifreeze proteins
BR112017010430A2 (pt) * 2014-11-18 2017-12-26 Pixarbio Corp composição para tratar dor aguda, pós-operatória ou crônica em um indivíduo, método para tratar um indivíduo tendo dor aguda, pós-operatória ou crônica e kit para produzir a composição

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
US4213963A (en) * 1978-12-14 1980-07-22 Janssen Pharmaceutica N.V. Fluspirilene-containing compositions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
JPS59147374A (ja) * 1983-02-10 1984-08-23 Fuji Xerox Co Ltd 電子写真複写機のブラシクリ−ニング方法
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
EP0200213B1 (en) * 1985-05-02 1992-07-22 Ciba-Geigy Ag Hydrogels with increased organic solvent soluble active agent loading capacity, their preparation and the use thereof
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
JPH0641286B2 (ja) * 1987-05-14 1994-06-01 信行 西井 自動包装装置
US4964606A (en) * 1989-10-26 1990-10-23 Ncr Corporation Overhead mount for a CRT

Also Published As

Publication number Publication date
DK238888A (da) 1988-11-05
IE63081B1 (en) 1995-03-22
KR960006059B1 (ko) 1996-05-08
IL86211A0 (en) 1988-11-15
AU1555888A (en) 1988-11-10
PT87381A (pt) 1989-05-31
PT87381B (pt) 1992-08-31
ES2043716T3 (es) 1994-01-01
JPH01131117A (ja) 1989-05-24
ATE94390T1 (de) 1993-10-15
US5122543A (en) 1992-06-16
HU199074B (en) 1990-01-29
DD269784A5 (de) 1989-07-12
MX11339A (es) 1993-12-01
DK169608B1 (da) 1994-12-27
HUT46847A (en) 1988-12-28
PH24895A (en) 1990-12-26
NO881933L (no) 1988-11-07
DK238888D0 (da) 1988-05-03
FI882044A (fi) 1988-11-05
EP0289977B1 (de) 1993-09-15
FI882044A0 (fi) 1988-05-02
NZ224476A (en) 1990-09-26
EP0289977A1 (de) 1988-11-09
NO881933D0 (no) 1988-05-03
AU619178B2 (en) 1992-01-23
CA1328219C (en) 1994-04-05
ZA883135B (en) 1988-11-07
DE3884044D1 (de) 1993-10-21
KR880013550A (ko) 1988-12-21
IE881328L (en) 1988-11-04

Similar Documents

Publication Publication Date Title
IL86211A (en) Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
ES2171158T3 (es) Derivados de oxatiolano cristalizados.
GB2235697B (en) Improved and property-balanced nickel-base superalloys for producing single crystal articles.
AU2045188A (en) Crystal article, method for producing the same and semiconductor device utilizing the same
EP0206541A3 (en) Gallium arsenide single crystals, and process for the preparation thereof
AR248407A1 (es) Un procedimiento para la preparacion de la forma monohidratada cristalina de una 1-carbacefalosporina.
HUT49563A (en) Process for producing optically active hydroxy-benzyl-amin derivatives, optically active amine-boron compounds containing them, and process for producing other optically active compounds with utilizing former optically active amine-boron compounds
GR890300066T1 (en) Dihydropyridazinone derivatives, method for their preparation and medicines containing the compounds
AU624617B2 (en) Sodium chloride in novel crystal form and aqueous solution containing the same
EP0325635A4 (en) PRODUCTION OF HBLV VIRUS IN THE HSB-2 CELL LINE.
EP0495485A3 (en) Phenoxyalkylcarboxylic acid derivatives, process of preparing the same and anti-allergic agents
ZA88990B (en) A process for the inactivation of viruses having envelopes in protein preparations prepared in vitro with the aid of a cell
AU2267188A (en) One-way valve, method for the production thereof and the use of the valve
AU4836790A (en) Pdgf-a, pdgf-aa, pdgf-ab, process for producing them and drugs containing them
MY103367A (en) Oral forms of administration with delayed release
GB2159433B (en) Chrysoberyl single crystal showing iridescent effect and process for its preparation
GB2192880B (en) 5-fluorouracil derivatives, process for preparing the same and their use
CS390989A3 (en) Pseudoprimycin complex, its components and their addition salts with acidsand process for preparing thereof
EP0322357A3 (en) Process for the preparation of polyazo dyes
AU4194489A (en) Milk constituents, process for producing them and agents containing them
AU2078588A (en) 9-halogen-(z)-prostaglandin derivatives, process for manufacturing them, and their use as drugs
HUT49593A (en) Fungicides comprising substituted pyrimidine derivatives and process for producing the active ingredients
AU1400488A (en) Dicyanoethylaryl derivatives and process for their preparation
GR81211B (en) Novel benzothiazol-2(3h)-on, method for the preparation thereof and drugs containing said compounds
EP0414018A3 (en) Process for the preparation of dehydrocycloclausenamide and its derivatives in the racemic form and as optically active (+)- or (-)-enantiomers